Author + information
To assess the long-term outcomes in patients with Stanford B aortic dissection treated with endovascular aortic repair with or without statins.
A retrospective review was performed on 388 Stanford B aortic dissection patients treated with endovascular repair in our department from April 2002 to October 2013. The patients were divided into two groups: statins group (118 cases) and non-statins group (270 cases). The baseline clinical features, laboratory data, in-hospital and long-term outcomes between the two groups were compared.
The incidence of hypertension and coronary heart disease (CHD) in the statins group was significantly higher than non-statins group (P =0.027, P <0.001). However, there was no differences between other clinical features(P >0.05). Compared with the non-statins group, the usage rate of aspirin is higher in statins group (P <0.001). There were no significant difference in stent grafts characteristics and in-hospital complication. The mortality in-hospital of the non-statins group was higher than the statins group, but the differences were no statistically significant (P =0.184). Through Kaplan-Meier analysis, the survival rate between two groups had no significant difference(P =0.472).
In our study, we conclude that statins, at the beginning of the trial, cannot improve in-hospital and long-term outcomes in patients with Stanford B aortic dissection treated with endovascular aortic repair.